343 related articles for article (PubMed ID: 24795429)
1. Autologous T-cell therapy for cytomegalovirus as a consolidative treatment for recurrent glioblastoma.
Schuessler A; Smith C; Beagley L; Boyle GM; Rehan S; Matthews K; Jones L; Crough T; Dasari V; Klein K; Smalley A; Alexander H; Walker DG; Khanna R
Cancer Res; 2014 Jul; 74(13):3466-76. PubMed ID: 24795429
[TBL] [Abstract][Full Text] [Related]
2. Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial.
Lim J; Park Y; Ahn JW; Sim J; Kang SJ; Hwang S; Chun J; Choi H; Kim SH; Chun DH; Sung KS; Kwack K; Cho K
PLoS One; 2021; 16(3):e0247293. PubMed ID: 33690665
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo functional analysis, expansion and adoptive transfer of cytomegalovirus-specific T-cells in patients with glioblastoma multiforme.
Crough T; Beagley L; Smith C; Jones L; Walker DG; Khanna R
Immunol Cell Biol; 2012 Oct; 90(9):872-80. PubMed ID: 22508289
[TBL] [Abstract][Full Text] [Related]
4. Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma.
Reap EA; Suryadevara CM; Batich KA; Sanchez-Perez L; Archer GE; Schmittling RJ; Norberg PK; Herndon JE; Healy P; Congdon KL; Gedeon PC; Campbell OC; Swartz AM; Riccione KA; Yi JS; Hossain-Ibrahim MK; Saraswathula A; Nair SK; Dunn-Pirio AM; Broome TM; Weinhold KJ; Desjardins A; Vlahovic G; McLendon RE; Friedman AH; Friedman HS; Bigner DD; Fecci PE; Mitchell DA; Sampson JH
Cancer Res; 2018 Jan; 78(1):256-264. PubMed ID: 29093005
[TBL] [Abstract][Full Text] [Related]
5. Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma.
Dillman RO; Duma CM; Ellis RA; Cornforth AN; Schiltz PM; Sharp SL; DePriest MC
J Immunother; 2009; 32(9):914-9. PubMed ID: 19816190
[TBL] [Abstract][Full Text] [Related]
6. Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastoma.
Ghazi A; Ashoori A; Hanley PJ; Brawley VS; Shaffer DR; Kew Y; Powell SZ; Grossman R; Grada Z; Scheurer ME; Hegde M; Leen AM; Bollard CM; Rooney CM; Heslop HE; Gottschalk S; Ahmed N
J Immunother; 2012; 35(2):159-68. PubMed ID: 22306904
[TBL] [Abstract][Full Text] [Related]
7. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe).
Mrugala MM; Engelhard HH; Dinh Tran D; Kew Y; Cavaliere R; Villano JL; Annenelie Bota D; Rudnick J; Love Sumrall A; Zhu JJ; Butowski N
Semin Oncol; 2014 Oct; 41 Suppl 6():S4-S13. PubMed ID: 25213869
[TBL] [Abstract][Full Text] [Related]
8. Autologous CMV-specific T cells are a safe adjuvant immunotherapy for primary glioblastoma multiforme.
Smith C; Lineburg KE; Martins JP; Ambalathingal GR; Neller MA; Morrison B; Matthews KK; Rehan S; Crooks P; Panikkar A; Beagley L; Le Texier L; Srihari S; Walker D; Khanna R
J Clin Invest; 2020 Nov; 130(11):6041-6053. PubMed ID: 32750039
[TBL] [Abstract][Full Text] [Related]
9. Bioactivity and Safety of IL13Rα2-Redirected Chimeric Antigen Receptor CD8+ T Cells in Patients with Recurrent Glioblastoma.
Brown CE; Badie B; Barish ME; Weng L; Ostberg JR; Chang WC; Naranjo A; Starr R; Wagner J; Wright C; Zhai Y; Bading JR; Ressler JA; Portnow J; D'Apuzzo M; Forman SJ; Jensen MC
Clin Cancer Res; 2015 Sep; 21(18):4062-72. PubMed ID: 26059190
[TBL] [Abstract][Full Text] [Related]
10. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
[TBL] [Abstract][Full Text] [Related]
11. Treatment of recurrent glioblastoma multiforme with GliaSite brachytherapy.
Chan TA; Weingart JD; Parisi M; Hughes MA; Olivi A; Borzillary S; Alahakone D; Detorie NA; Wharam MD; Kleinberg L
Int J Radiat Oncol Biol Phys; 2005 Jul; 62(4):1133-9. PubMed ID: 15990019
[TBL] [Abstract][Full Text] [Related]
12. Response patterns of recurrent glioblastomas treated with tumor-treating fields.
Vymazal J; Wong ET
Semin Oncol; 2014 Oct; 41 Suppl 6():S14-24. PubMed ID: 25213870
[TBL] [Abstract][Full Text] [Related]
13. Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial.
Weathers SP; Penas-Prado M; Pei BL; Ling X; Kassab C; Banerjee P; Bdiwi M; Shaim H; Alsuliman A; Shanley M; de Groot JF; O'Brien BJ; Harrison R; Majd N; Kamiya-Matsuoka C; Fuller GN; Huse JT; Chi L; Rao G; Weinberg JS; Lang FF; Sawaya R; Shpall EJ; Rezvani K; Heimberger AB
Clin Cancer Res; 2020 Jul; 26(14):3565-3577. PubMed ID: 32299815
[TBL] [Abstract][Full Text] [Related]
14. High-dose chemotherapy and adoptive immunotherapy in the treatment of recurrent pediatric brain tumors.
Peres E; Wood GW; Poulik J; Baynes R; Sood S; Abidi MH; Klein J; Bhambhani K; Dansey R; Abella E
Neuropediatrics; 2008 Jun; 39(3):151-6. PubMed ID: 18991194
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
16. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
Hong B; Wiese B; Bremer M; Heissler HE; Heidenreich F; Krauss JK; Nakamura M
Am J Clin Oncol; 2013 Jun; 36(3):261-8. PubMed ID: 22495452
[TBL] [Abstract][Full Text] [Related]
17. Stereotactic radiosurgery (SRS): treatment option for recurrent glioblastoma multiforme (GBM).
Combs SE; Widmer V; Thilmann C; Hof H; Debus J; Schulz-Ertner D
Cancer; 2005 Nov; 104(10):2168-73. PubMed ID: 16220556
[TBL] [Abstract][Full Text] [Related]
18. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
O'Rourke DM; Nasrallah MP; Desai A; Melenhorst JJ; Mansfield K; Morrissette JJD; Martinez-Lage M; Brem S; Maloney E; Shen A; Isaacs R; Mohan S; Plesa G; Lacey SF; Navenot JM; Zheng Z; Levine BL; Okada H; June CH; Brogdon JL; Maus MV
Sci Transl Med; 2017 Jul; 9(399):. PubMed ID: 28724573
[TBL] [Abstract][Full Text] [Related]
19. Effects of local injection of ex vivo expanded autologous tumor-specific T lymphocytes in cases with recurrent malignant gliomas.
Tsuboi K; Saijo K; Ishikawa E; Tsurushima H; Takano S; Morishita Y; Ohno T
Clin Cancer Res; 2003 Aug; 9(9):3294-302. PubMed ID: 12960115
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme.
Francesconi AB; Dupre S; Matos M; Martin D; Hughes BG; Wyld DK; Lickliter JD
J Clin Neurosci; 2010 Aug; 17(8):970-4. PubMed ID: 20541421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
